Provided by Tiger Trade Technology Pte. Ltd.

Anbio Biotechnology

6.37
+0.31005.12%
Volume:60.14K
Turnover:388.88K
Market Cap:916.59M
PE:43.44
High:6.76
Open:6.04
Low:6.04
Close:6.06
52wk High:51.33
52wk Low:5.13
Shares:143.89M
Float Shares:39.69M
Volume Ratio:0.75
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1466
EPS(LYR):0.1466
ROE:27.05%
ROA:14.66%
PB:30.40
PE(LYR):43.44

Loading ...

Anbio Biotechnology trading halted, volatility trading pause

TIPRANKS
·
Aug 17

NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am

Reuters
·
Aug 17

Anbio Biotechnology trading halted, volatility trading pause

TIPRANKS
·
Jul 31

NASDAQ Trade Halt Volatility Trading Pause at 01:41 Pm

Reuters
·
Jul 31

U.S. Small Caps Finish Mixed as Polibeli Group Leads, Anbio Biotechnology Lags

Dow Jones
·
Jul 11

Anbio Biotechnology Files Mixed Shelf Registration

MT Newswires Live
·
Jul 10

Anbio Biotechnology files automatic mixed securities shelf

TIPRANKS
·
Jul 10

Anbio Biotechnology director David Hsu files initial beneficial ownership statement

Reuters
·
Jun 12

Anbio Biotechnology falls -22.7%

TIPRANKS
·
Jun 09

Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
May 24

Anbio Biotechnology Shareholders Approve Sweeping Capital and Governance Changes

TIPRANKS
·
May 19

Anbio Biotechnology shareholders approve restated charter at extraordinary general meeting

Reuters
·
May 19

Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul

TIPRANKS
·
Apr 28

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

Benzinga_recent_news
·
Apr 10

Anbio Biotechnology CFO Suki Song files initial beneficial ownership statement

Reuters
·
Apr 09

Anbio Biotechnology director Nancy Hartzler files initial beneficial ownership statement

Reuters
·
Apr 09

Anbio Biotechnology CEO Michael Lau files initial beneficial ownership statement

Reuters
·
Apr 09

Anbio Biotechnology CBO Chris Tian files initial beneficial ownership statement

Reuters
·
Apr 09

Anbio Biotechnology director Cany Xu files initial beneficial ownership statement

Reuters
·
Apr 09

Anbio Biotechnology FY25 net income more than doubled to $6.4 million; revenue rises 5.64% to $8.6 million

Reuters
·
Apr 08